Prognosis of patients with stable angina pectoris on antianginal drug therapy

American Journal of Cardiology

Volumn 77, Issue 16, 1996, Pages

  Hjemdahl, Paul ^a   Eriksson, Sven V ^b   Held, Claes ^b   Rehnqvist, Nina ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; NIFEDIPINE; VERAPAMIL;

ANGINA PECTORIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SCREENING; HEART INFARCTION; HUMAN; INCIDENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0029951542     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00301-3     Document Type: Article

References (67)

1. Richards DW, Bland EF, White PD. A completed twenty-five-year follow-up study of 456 patients with angina pectoris. J Chron Dis 1956;4:423-433.
2. Goldman GJ, Pichard AD. The natural history of coronary artery disease: does medical therapy improve the prognosis? Prog Cardiovasc Dis 1983;25:513-552.
3. Rosengren A, Hagman M, Pennert K, Wilhelmsen L. Clinical course and symptomatology of angina pectoris in a population study. Acta Med Scand 1986;220:117-126.
4. Murabito JM, Anderson KM, Kannel WB, Evans JC, Levy D. Risk of coronary heart disease in subjects with chest discomfort: the Framingham heart study. Am J Med 1990;89:297-302.
5. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease - an investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993;88:2548-2555.
6. Heberden W. Some account of a disorder of the breast. Med Transact Coll Physicians 1778;2:59-67.
7. Maseri A. Medical therapy of chronic stable angina pectoris. Circulation 1990;82:2258-2262.
8. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990;81:748-756.
9. Mulcahy D, Fox K. Therapeutic implications of ischemia in the ambulatory setting. Prog Cardiovasc Dis 1992;34:413-428.
10. Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J 1995;73:193-198.
11. White PD. The prognosis of angina pectoris and of coronary thrombosis. JAMA 1926;87:1525-1530.
12. Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features. Br Med J 1994;308:883-886.
13. Chambers J, Bass C. Chest pain with normal coronary anatomy: a review of natural history and possible etiologic factors. Prog Cardiovasc Dis 1990;33:161-184.
14. Cannon RO. Angina pectoris with normal coronary angiograms. Cardiol Clin 1991;9:157-166.
15. Lichtlen PR, Bargheer K, Wenzlaf P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. J Am Coll Cardiol 1995:25:1013-1018.
16. Oriencia A, Bailey K, Yawn BP, Kottke TE. Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden unexpected death. JAMA 1993;269:2392-2397.
17. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR, Chaitman, BR, Kaiser GC, Alderman E, Killip T III, and Participants in the Coronary Artery Surgery Study (CASS). Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994;90:2645-2657.
18. Yusuf S, Zucker D, Peduzzi P, Fischer L, Takaro T, Kennedy W, Davis K, Killip T, Passamani E, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers T. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Surgery Trialists Collaboration. Lancet 1994;344:563-570.
19. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs Investigators. N Engl J Med 1992;326:10-16.
20. The Swedish Council on Technology Assessment in Health Care (SBU). Coronary artery bypass graft and percutaneous transluminal coronary angioplasty. SBU report no. 120E.
21. Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta blockers for optimal antianginal therapy. Clin Cardiol 1994;17:415-421.
22. Weiner DA. Calcium antagonists in the treatment of ischemic heart disease: angina pectoris. Coron Artery Dis 1994;5:14-20.
23. Tolins M, Weir EK, Chesler E, Pierpont GL. "Maximal" drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984;3:1051-1057.
24. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation 1991;84:2598-2600.
25. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet treatment - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
26. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low dose aspirin therapy for chronic stable angina. A randomized placebo-controlled clinical trial. Ann Intern Med 1991;114:835-839.
27. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Serensen S, Ömblus R, for the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.
28. Hjemdahl P. Platelet reactivity, exercise, and stable coronary artery disease. Eur Heart J 1995;16:1017-1019.
29. Melandri G, Semprini F, Cervi V, Candotti N, Palazzini E, Branzi A, Magnani B. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris - a double-blind, randomized, placebo-controlled trial. Circulation 1993;88:2517-2523.
30. Henry PD. Atherosclerosis, calcium, and calcium antagonists. Circulation 1985;72:456-459.
31. Parmley WW. Vascular protection from atherosclerosis: potential of calcium antagonists. Am J Cardiol 1990;66(suppl):161-221.
32. Kaplan JR, Manuck SB, Adams MR, Clarkson TB. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J 1987;8:928-944.
33. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT group. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-1113.
34. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
35. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
36. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993;11(suppl 4):S61-S73.
37. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction trials. Am J Cardiol 1986;57(suppl 12):43F-49F.
38. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double-blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986;56:400-413.
39. Koon KT, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993;270:1589-1595.
40. Pedersen TR, for the Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction - a multicenter study on timolol in secondary prevention after infarction. Acta Med Scand 1983;(suppl 679):1-129.
41. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.
42. Olsson G, Rehnqvist N, Freyschuss U, Zetterquist S. Influence of long-term metoprolol treatment on early and late exercise test performance after myocardial infarction. Am J Cardiol 1988;61:519-523.
43. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989;299:1187-1192.
44. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1992;67:1295-1297.
45. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
46. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-528.
47. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.
48. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
49. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669-685.
50. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E, Marks RG, Thadani U, for the ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life - the Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-768.
51. The TIBET Study Group. The Total Ischemic Burden European Trial (TIBET): design, methodology and management. Cardiovasc Drugs Ther 1992;6:379-386.
52. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Total Ischaemic Burden European Trial (TIBET): effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome. Eur Heart J 1996;17:104-112.
53. Hjalmarsson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 1981;ii:823-827.
54. Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction. Report on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-1437.
55. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, Held C, Näsman P, Wallén NH. Effects of metoprolol versus verapamil treatment in patients with stable angina pectoris - the Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996;17:76-81. (Erratum p.483)
56. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183.
57. Swedish Council on Technology Assessment in Health Care. Moderately elevated Wood pressure. J Intern Med 1995;238 (suppl 737):1-225.
58. Opie LH, Messerli FH. Nifedipine and mortality - grave defects in the dossier. Circulation 1995;92:1068-1073.
59. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92:1074-1078.
60. Karlsson BW, Emanuelsson H, Herlitz J, Nilsson J-E, Olsson G. Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics. Eur J Clin Pharmacol 1991;40:501-506.
61. Yusuf S. Calcium antagonists in coronary artery disease and hypertension - time for reevaluation? Circulation 1995;92:1079-1082.
62. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
63. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A. Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481-487.
64. Aursnes I, Litleskare I, Frøyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press 1995;4:157-163.
65. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction - a hypothesis formulated but not yet tested. JAMA 1995;274:654-655.
66. Malmberg K, Herlitz J, Hjalmarsson Å, Rydén L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989;10:423-428.
67. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994;11:137-144.